Skip to main content

Table 4 The significant SNP associations with breast cancer considering allelic and Cochran-Armitage trend tests

From: Common low-penetrance risk variants associated with breast cancer in Polish women

dbSNP IDa

Region

Geneb

MA

G1 vs G2

OR (95% CI)

Allelic

Cochran-Armitage

p-value

p-valuecor

p-value

p-valuecor

rs10941679

5p12

 

0.24

C vs N

1.14 (1.01-1.28)

2.97E-02

4.75E-01

2.71E-02

4.34E-01

    

C noMut vs N

1.15 (1.02-1.30)

2.29E-02

3.66E-01

2.04E-02

3.27E-01

    

S vs N

1.17 (1.01-1.35)

4.25E-02

6.80E-01

3.94E-02

6.31E-01

    

S noMut vs N

1.20 (1.03-1.40)

2.06E-02

3.29E-01

1.87E-02

2.99E-01

rs2736098

5p15.33

TERT

0.36

C vs N

0.77 (0.68-0.88)

5.81E-05

9.30E-04

5.51E-05

8.82E-04

    

C noMut vs N

0.78 (0.69-0.89)

2.37E-04

3.78E-03

2.25E-04

3.60E-03

    

C with Mut vs N

0.74 (0.57-0.94)

1.70E-02

2.73E-01

1.55E-02

2.48E-01

    

F vs N

0.81 (0.69-0.93)

4.68E-03

7.49E-02

4.56E-03

7.30E-02

    

F noMut vs N

0.80 (0.68-0.94)

8.63E-03

1.38E-01

8.25E-03

1.32E-01

    

S vs N

0.74 (0.63-0.87)

2.61E-04

4.17E-03

2.38E-04

3.80E-03

    

S noMut vs N

0.76 (0.64-0.90)

1.46E-03

2.34E-02

1.36E-03

2.18E-02

rs13281615

8q24.21

 

0.45

C vs N

1.19 (1.07-1.32)

1.23E-03

1.97E-02

1.17E-03

1.88E-02

    

C noMut vs N

1.21 (1.08-1.35)

7.23E-04

1.16E-02

6.77E-04

1.08E-02

    

F vs N

1.20 (1.06-1.35)

5.19E-03

8.31E-02

5.24E-03

8.39E-02

    

F noMut vs N

1.22 (1.06-1.39)

4.60E-03

7.36E-02

4.53E-03

7.25E-02

    

S vs N

1.18 (1.03-1.35)

1.61E-02

2.57E-01

1.42E-02

2.27E-01

    

S noMut vs N

1.20 (1.04-1.38)

1.09E-02

1.74E-01

9.61E-03

1.54E-01

rs1219648

10q26

FGFR2

0.41

C vs N

1.30 (1.17-1.45)

1.01E-06

1.62E-05

1.13E-06

1.81E-05

    

C noMut vs N

1.36 (1.22-1.52)

7.20E-08

1.15E-06

7.95E-08

1.27E-06

    

F vs N

1.26 (1.11-1.43)

4.21E-04

6.73E-03

3.76E-04

6.01E-03

    

F noMut vs N

1.33 (1.16-1.53)

4.02E-05

6.43E-04

3.24E-05

5.18E-04

    

S vs N

1.36 (1.19-1.56)

7.32E-06

1.17E-04

8.53E-06

1.36E-04

    

S noMut vs N

1.39 (1.20-1.59)

5.58E-06

8.92E-05

6.76E-06

1.08E-04

rs2981582

10q26

FGFR2

0.41

C vs N

1.31 (1.17-1.45)

9.10E-07

1.46E-05

1.17E-06

1.88E-05

    

C noMut vs N

1.35 (1.21-1.51)

1.20E-07

1.91E-06

1.54E-07

2.46E-06

    

F vs N

1.26 (1.11-1.43)

4.05E-04

6.48E-03

4.09E-04

6.54E-03

    

F noMut vs N

1.32 (1.15-1.51)

6.49E-05

1.04E-03

6.11E-05

9.77E-04

    

S vs N

1.37 (1.19-1.56)

5.70E-06

9.12E-05

7.67E-06

1.23E-04

    

S noMut vs N

1.38 (1.20-1.59)

5.69E-06

9.11E-05

7.97E-06

1.27E-04

rs3817198

11p15.5

LSP1

0.34

F vs N

1.16 (1.02-1.32)

2.45E-02

3.92E-01

2.36E-02

3.78E-01

    

F noMut vs N

1.16 (1.00-1.33)

4.46E-02

7.14E-01

4.34E-02

6.94E-01

rs3803662

16q12.1

TOX3

0.30

C vs N

1.13 (1.01-1.27)

3.14E-02

5.02E-01

3.22E-02

5.15E-01

    

C noMut vs N

1.16 (1.03-1.31)

1.30E-02

2.08E-01

1.35E-02

2.16E-01

    

F noMut vs N

1.16 (1.00-1.34)

4.45E-02

7.11E-01

4.53E-02

7.25E-01

    

S noMut vs N

1.16 (1.00-1.35)

4.75E-02

7.61E-01

4.82E-02

7.71E-01

  1. Bold denotes significant association after multiple testing adjustment (p-value cor < 0.05). G1 vs. G2; compared groups of cases and controls, respectively, MA; minor allele (+) strand frequency, OR; odds ratio, CI; confidence interval, N; control, C; cancer (all cases), F; familial cancer, S; sporadic cancer, noMut; non-mutation carriers.
  2. a/SNP identifier based on NCBI SNP database;
  3. b/NCBI ID of genes localized in proximity to the SNPs of interest (source: HapMap).